The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...

J&J files Tremfya in psoriatic arthritis, its second indication, ... (ustekinumab) – has been approved in the US for moderate-to-severe plaque psoriasis since 2017.

The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting.

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

Bio-Thera receives positive CHMP opinion for Usymro, a biosimilar referencing Stelara: Guangzhou, China Monday, June 23, 2025, 15:00 Hrs [IST] Bio-Thera Solutions Inc., a commerci ...

The FDA approved a new presentation of Steqeyma®, for the treatment of pediatric patients with plaque psoriasis or psoriatic arthritis.

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

A large PsA cohort study found metabolic syndrome linked to spine and enthesis degeneration, but not to radiographic joint ...